General Information of Drug (ID: DMR0S8X)

Drug Name
4-hydroxy-3-nitrobenzaldehyde Drug Info
Synonyms
4-Hydroxy-3-nitrobenzaldehyde; 3011-34-5; Benzaldehyde, 4-hydroxy-3-nitro-; 3-nitro-4-hydroxybenzaldehyde; CHEMBL378361; 4-hydroxy-3-nitro-benzaldehyde; 4-FORMYL-2-NITROPHENOL; YTHJCZRFJGXPTL-UHFFFAOYSA-N; 4-Hydroxy-3-nitrobenzaldehyde, 97%; EINECS 221-141-6; NSC138267; NSC 138267; PubChem8135; ACMC-1CJNU; AC1L2BHN; 4-hydroxy-3-nitrobenzaldeyde; KSC223K5F; SCHEMBL244093; 4-hydroxyl-3-nitrobenzaldehyde; 4-Hydroxy-3-nitro benzaldehyde; Jsp005694; KS-00000AYN; CTK1C3552; DTXSID80184195; MolPort-000-156-359; ZINC562702; ACT01022
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
18169
CAS Number
CAS 3011-34-5
TTD Drug ID
DMR0S8X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting GABA transaminase (ABAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Alanine DMZDN4W Dietary shortage 5B5K Approved [2]
Pyridoxal Phosphate DMO2K0J Malnutrition 5B50-5B71 Approved [2]
Pyruvic acid DM7Q41G Malnutrition 5B50-5B71 Approved [2]
Vigabatrin DMYT0OG Alcohol dependence 6C40.2 Approved [3]
Divalproex sodium DM4RK0G Seizure disorder 8A6Z Approved [2]
CPP-115 DMK9NQI Tourette syndrome 8A05.00 Phase 2 [4]
K-828-AB DMJLNZQ Dementia 6D80-6D86 Phase 2 [5]
CPP -15 DMQCHU3 Infantile spasm 8A62.0 Phase 1 [4]
T83193 DMHO29Y Discovery agent N.A. Patented [1]
4-hydroxybenzaldehyde DM471P5 Discovery agent N.A. Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA transaminase (ABAT) TTT2LD9 GABT_HUMAN Inhibitor [1]

References

1 Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
2 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 Clinical pipeline report, company report or official report of Catalyst Pharma.
5 Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
6 Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.